• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Prenetics Global Limited (Amendment)

    3/27/23 11:02:05 AM ET
    $PRE
    Blank Checks
    Finance
    Get the next $PRE alert in real time by email
    SC 13D/A 1 d487948dsc13da.htm SCHEDULE 13D AMENDMENT NO. 1 Schedule 13D Amendment No. 1

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Prenetics Global Limited

    (Name of Issuer)

    Class A ordinary shares, US$0.0001 par value per share

    (Title of Class of Securities)

    G72245106

    (CUSIP Number)

    Da Yeung Limited

    Yeung Danny Sheng Wu

    Unit 701-706, K11 Atelier King’s Road

    728 King’s Road, Quarry Bay

    Hong Kong

    Tel: +852-2210-9588

    January 3, 2023

    (Date of Event Which Requires Filing of This Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

     

     

     

    *

    This statement on Schedule 13D constitutes Amendment No. 1 to the initial Schedule 13D (the “Original Schedule 13D”) filed on May 31, 2022 on behalf of each of Da Yeung Limited and Yeung Danny Sheng Wu, with respect to ordinary shares (“Ordinary Shares”), comprising Class A ordinary shares, par value US$0.0001 per share (“Class A Ordinary Shares”), and Class B ordinary shares, par value US$0.0001 per share (“Class B Ordinary Shares”), of Prenetics Global Limited (the “Issuer”), an exempted company limited by shares incorporated under the laws of the Cayman Island.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    SCHEDULE 13D      Page __ of __

     

    CUSIP No. G72245106  

     

      (1)   

      Names of reporting persons

     

      Da Yeung Limited

      (2)  

      Check the appropriate box if a member of a group (see instructions)

      (a)  ☐        (b)  ☐

     

      (3)  

      SEC use only

     

      (4)  

      Source of funds (see instructions)

     

      OO

      (5)  

      Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

      (6)  

      Citizenship or place or organization

     

      British Virgin Islands

    Number of

    shares

    beneficially

    owned by

    each

    reporting

    person

    with:

     

         (7)   

      Sole voting power

     

      9,713,864(1)

         (8)  

      Shared voting power

     

         (9)  

      Sole dispositive power

     

      9,713,864(1)

       (10)  

      Shared dispositive power

     

    (11)  

      Aggregate amount beneficially owned by each reporting person

     

      9,713,864(1)

    (12)  

      Check if the aggregate amount in Row (11) excludes certain shares (see instructions)

     

    (13)  

      Percent of class represented by amount in Row (11)

     

      6.12%(2)

    (14)  

      Type of reporting person (see instructions)

     

      CO

     

    (1)

    Represents 9,713,864 Class B Ordinary Shares directly held by Da Yeung Limited, a British Virgin Islands company wholly owned by Yeung Danny Sheng Wu. Each Class B Ordinary Share is convertible at the option of the holder into one Class A Ordinary Share. Class A Ordinary Shares are not convertible into Class B Ordinary Shares under any circumstances. The rights of the holders of Class A Ordinary Shares and Class B Ordinary Shares are identical, except with respect to conversion rights (noted above) and voting rights. Each Class B Ordinary Share is entitled to twenty (20) votes, whereas each Class A Ordinary Share is entitled to one vote.

    (2)

    Calculated based on 158,820,280 Ordinary Shares as a single class (being the sum of 136,775,834 Class A Ordinary Shares and 22,044,446 Class B Ordinary Shares) to which this report is related, issued and outstanding as of January 12, 2023. The Class B Ordinary Shares are treated as converted into Class A Ordinary Shares only for the purpose of calculating the percentage of ownership of the Reporting Person.


    CUSIP No. G72245106   

     

      (1)   

      Names of reporting persons

     

      Yeung Danny Sheng Wu

      (2)  

      Check the appropriate box if a member of a group (see instructions)

      (a)  ☐        (b)  ☐

     

      (3)  

      SEC use only

     

      (4)  

      Source of funds (see instructions)

     

      OO

      (5)  

      Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

      (6)  

      Citizenship or place or organization

     

       Hong Kong SAR

    Number of

    shares

    beneficially

    owned by

    each

    reporting

    person

    with:

     

         (7)   

      Sole voting power

     

      22,044,446(1)

         (8)  

      Shared voting power

     

         (9)  

      Sole dispositive power

     

      22,044,446(1)

       (10)  

      Shared dispositive power

     

    (11)  

      Aggregate amount beneficially owned by each reporting person

     

      22,044,446(1)

    (12)  

      Check if the aggregate amount in Row (11) excludes certain shares (see instructions)

     

    (13)  

      Percent of class represented by amount in Row (11)

     

      13.88%(2)

    (14)  

      Type of reporting person (see instructions)

     

      IN

     

    (1)

    Represents (i) 12,330,582 Class B Ordinary Shares directly held by Yeung Danny Sheng Wu, and (ii) 9,713,864 Class B Ordinary Shares held by Da Yeung Limited, a British Virgin Islands company wholly owned by Yeung Danny Sheng Wu. Each Class B Ordinary Share is convertible at the option of the holder into one Class A Ordinary Share. Class A Ordinary Shares are not convertible into Class B Ordinary Shares under any circumstances. The rights of the holders of Class A Ordinary Shares and Class B Ordinary Shares are identical, except with respect to conversion rights (noted above) and voting rights. Each Class B Ordinary Share is entitled to twenty (20) votes, whereas each Class A Ordinary Share is entitled to one vote.

    (2)

    Calculated based on 158,820,280 Ordinary Shares as a single class (being the sum of 136,775,834 Class A Ordinary Shares and 22,044,446 Class B Ordinary Shares) to which this report is related, issued and outstanding as of January 12, 2023, assuming conversion of all Class B Ordinary Shares into Class A Ordinary Shares. The Class B Ordinary Shares are treated as converted into Class A Ordinary Shares only for the purpose of calculating the percentage of ownership of the Reporting Person.


    SCHEDULE 13D    Page ___ of ___

    Pursuant to Rule 13d-2 promulgated under the Act, This Amendment No. 1 (this “Amendment No. 1”), amends and supplements the Original Schedule 13D. Except as otherwise set forth herein, this Amendment No. 1 does not modify any of the information previously reported in the Original Schedule 13D. Capitalized terms used in this Amendment No. 1 and not otherwise defined herein shall have the same meanings ascribed to them in the Original Schedule 13D.

    Item 3. Source and Amount of Funds or Other Consideration.

    Item 3 is hereby amended and supplemented by adding the following at the end thereof:

    On December 31, 2022, Danny exercised 6,064,923 restricted share units in exchange for 12,330,582 Class B Ordinary Shares pursuant to the Issuer’s 2022 Share Incentive Plan.

    Item 4. Purpose of Transaction.

    Item 4 is hereby amended and supplemented by (i) adding the following after the section under the heading “Lock-Up Provision”, and (ii) amending and restating the first paragraph of the section under the heading “General”.

    Share Incentive Plan

    Danny exercised 6,064,923 restricted share units in exchange for 12,330,582 Class B Ordinary Shares pursuant to the Issuer’s 2022 Share Incentive Plan.

    Item 5. Interest in Securities of the Issuer.

    Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows:

    (a) and (b):The responses of each Reporting Person to Rows (7) through (13) of the cover pages of this Schedule 13D are hereby incorporated by reference in this Item 5.

    The percentage of the class of securities identified pursuant to Item 1 beneficially owned by the Reporting Person is based on a total of 158,820,280 issued and outstanding Ordinary Shares (consisting of 136,775,834 Class A Ordinary Shares and 22,044,446 Class B Ordinary Shares) of the Issuer as of January 12, 2023. Each Class B Ordinary Share is convertible at the option of the holder into one Class A Ordinary Share. Class A Ordinary Shares are not convertible into Class B Ordinary Shares under any circumstances. The rights of the holders of Class A Ordinary Shares and Class B Ordinary Shares are identical, except with respect to conversion rights (noted above) and voting rights. Each Class B Ordinary Share is entitled to twenty (20) votes, whereas each Class A Ordinary Share is entitled to one vote.

    The shares beneficially owned by Da Yeung Limited represent approximately 6.12% of the total issued and outstanding ordinary shares of the Issuer and represent approximately 33.63% of the aggregate voting power of the Issuer’s total issued and outstanding ordinary shares.

    The shares beneficially owned by Danny represent approximately 13.88% of the total issued and outstanding ordinary shares of the Issuer and represent approximately 76.32% of the aggregate voting power of the Issuer’s total issued and outstanding ordinary shares.

    (c): Except as disclosed in this Schedule 13D, none of the Reporting Persons has effected any transaction in the Ordinary Shares during the past 60 days.

    (d): None.

    (e): Not applicable.


    Item 7. Materials to be Filed as Exhibits.

    Item 7 of the Original Schedule 13D is hereby amended and restated as follows:

     

    Exhibit
    No.
      

    Description

    A    Joint Filing Agreement dated May  31, 2022 by and between the Reporting Persons (previously filed with the SEC as Exhibit A to the Original Schedule 13D filed by the Reporting Persons on May 31, 2022).
    B    Registration Rights Agreement, dated as of September  15, 2021, by and among Prenetics Global Limited, Artisan Acquisition Corp., Artisan LLC, Danny Sheng Wu Yeung and other parties named therein (incorporated by reference to Exhibit 10.5 to the Registration Statement on Form F-1 (File No. 333-265284) filed with the SEC on May 27, 2022).
    C    Shareholder Support Agreements and Deed, dated as of September  15, 2021, by and among Prenetics Global Limited, Prenetics Group Limited, Artisan Acquisition Corp., and certain management shareholders named therein (incorporated by reference to Exhibit 10.6 to the Registration Statement on Form F-1 (File No. 333-265284) filed with the SEC on May 27, 2022).
    D    Amendment to Shareholder Support Agreement, dated as of March  30, 2022, by and among Prenetics Global Limited, Prenetics Group Limited, Artisan Acquisition Corp. and certain management shareholders named therein (incorporated by reference to Exhibit 10.23 to the Registration Statement on Form F-1 (File No. 333-265284) filed with the SEC on May 27, 2022).
    E    Prenetics Global Limited 2022 Share Incentive Plan (incorporated herein by reference to Exhibit 4.4 to the Form 20-F transition report filed with the SEC on May 27, 2022)


    Signatures

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

        Yeung Danny Sheng Wu
    Date: March 27, 2023     Signature:   /s/ Yeung Danny Sheng Wu
        Name:   Yeung Danny Sheng Wu

     

        Da Yeung Limited
    Date: March 27, 2023     Signature:   /s/ Yeung Danny Sheng Wu
        Name:   Yeung Danny Sheng Wu
        Title:   Director
    Get the next $PRE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PRE

    DatePrice TargetRatingAnalyst
    1/18/2023$7.00Overweight
    Cantor Fitzgerald
    7/12/2022Buy
    Citigroup
    More analyst ratings

    $PRE
    SEC Filings

    View All

    SEC Form 6-K filed by Prenetics Global Limited

    6-K - Prenetics Global Ltd (0001876431) (Filer)

    1/6/26 8:03:45 AM ET
    $PRE
    Blank Checks
    Finance

    SEC Form 6-K filed by Prenetics Global Limited

    6-K - Prenetics Global Ltd (0001876431) (Filer)

    1/5/26 8:20:41 AM ET
    $PRE
    Blank Checks
    Finance

    SEC Form 6-K filed by Prenetics Global Limited

    6-K - Prenetics Global Ltd (0001876431) (Filer)

    12/30/25 8:22:21 AM ET
    $PRE
    Blank Checks
    Finance

    $PRE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Prenetics Reinforces Strategic Focus on IM8, Divests Europa Business For Up to $13 Million

    Company Continues Portfolio Optimization on the Heels of Successful $72 million ACT Genomics sale Company Maintains Strong Balance Sheet with over $70 million in Cash and Cash Equivalents, 510 BTC and Zero Debt, representing approximately $118 million in Total Liquidity CHARLOTTE, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company and parent of the IM8 premium health and longevity brand, today announced that it has completed the sale of its 3PL distribution business operated by its subsidiary, Europa Sports Partners. The all-stock transaction is valued at up to $13 million, subject to the achieve

    1/6/26 8:00:00 AM ET
    $PRE
    Blank Checks
    Finance

    Prenetics Provides Update on Voluntary Warrant Exchange Program, Reaching 86.7% Participation

    CHARLOTTE, N.C., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company and parent of the IM8 premium health and longevity brand, today announced an update to its previously announced voluntary warrant exchange program. Updated Participation and Impact In connection with the Company's prior financing round in October 2025, 2,722,642 Class A ordinary shares were issued, with one Class A warrant and one Class B warrant issued for each such Class A ordinary share, for a total of 5,445,284 warrants. As of the date of this announcement, the Company has entered into exchange agreements covering 4,720,832 of the

    1/5/26 8:00:00 AM ET
    $PRE
    Blank Checks
    Finance

    Prenetics Announces Update to Capital Allocation Strategy; Ceases Bitcoin Purchases to Focus on IM8

    Company's Capital and Strategic Focus Now Exclusively Focused on IM8 IM8 FY 2026 Revenue Projected to Reach $180 - $200 Million CHARLOTTE, N.C., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, and parent of the IM8 premium health and longevity brand, today announced a strategic realignment to fully capitalize on the rapid growth of its consumer health brand, IM8. Prenetics ceased its daily Bitcoin purchasing activity as of December 4, 2025, and following approval by its Board of Directors, Prenetics announced that it will no longer pursue future acquisitions of Bitcoin. This decision allows Preneti

    12/30/25 8:00:00 AM ET
    $PRE
    Blank Checks
    Finance

    $PRE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Prenetics Group Ltd. with a new price target

    Cantor Fitzgerald initiated coverage of Prenetics Group Ltd. with a rating of Overweight and set a new price target of $7.00

    1/18/23 7:56:45 AM ET
    $PRE
    Blank Checks
    Finance

    Citigroup initiated coverage on Prenetics Group Ltd.

    Citigroup initiated coverage of Prenetics Group Ltd. with a rating of Buy

    7/12/22 11:48:35 AM ET
    $PRE
    Blank Checks
    Finance

    $PRE
    Financials

    Live finance-specific insights

    View All

    Prenetics Reports Record Third Quarter 2025 Results; IM8 on Track for $120M ARR¹ by December 2025, Fastest Supplement Brand Growth in Industry History

    Total Revenue Surges 568% YoY to $23.6 million; IM8 Monthly Revenue Hits Record US$9 million in October; Bitcoin Treasury Reaches 387 BTC (~$40M); IM8 Projects $180 - $200M FY 2026 Revenue, $25M Monthly Revenue or $300M ARR by Year End 2026 IM8 Delivers 60% Gross Margin, 3.9 Months Payback Period, Demonstrating Strong Unit Economics Company to Host Earnings Call Today at 8:30am ET, Releases Inaugural Quarterly Shareholder Letter CHARLOTTE, N.C., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company and parent of the IM8 premium health and longevity brand, today announced third quarter 2025 financial

    11/10/25 7:24:27 AM ET
    $EXOD
    $PRE
    Finance: Consumer Services
    Finance
    Blank Checks

    Prenetics Announces Third Quarter 2025 Financial Results Release Date and Inaugural Earnings Conference Call

    CHARLOTTE, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, today announced it will release financial results for the third quarter 2025 ended September 30, 2025 before market open on Monday, November 10, 2025. The Company will also hold its first ever earnings conference call the same day at 8:30 a.m. Eastern Time to discuss its financial results in further detail. The call will conclude with a Q&A session with analysts. Date:Monday, November 10, 2025Time:8:30 a.m. Eastern TimeDial-in:1-844-425-9470International Dial-in:201-298-0878WebcastPRE Conference Call An audio replay of the webcast will

    11/4/25 4:05:00 PM ET
    $PRE
    Blank Checks
    Finance

    Prenetics Bolsters Bitcoin Treasury with Strategic Acquisition of 100 Bitcoin, IM8 Reaches $100M ARR

    Additional Bitcoin Acquisition Follows Immediately on $44 Million Equity Offering Company now holds a total of 378 BTC (valued at ~$46 Million) CHARLOTTE, N.C., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, today announces the acquisition of 100 Bitcoin, at an average price of $109,594 per Bitcoin. This acquisition demonstrates the Company's dedication and continued discipline to building its Bitcoin treasury. Strategic Capital Deployment Following Successful Equity Raise This Bitcoin acquisition represents the initial deployment of proceeds from Prenetics' recently completed $44 million equity

    10/31/25 8:31:50 AM ET
    $PRE
    Blank Checks
    Finance

    $PRE
    Leadership Updates

    Live Leadership Updates

    View All

    Prenetics Becomes First Healthcare Company to Execute Aggressive Bitcoin Treasury Strategy, Secures $20M in BTC, Appoints Former OKEx COO to Board

    -  Prenetics adopts proven corporate Bitcoin strategy inspired by MicroStrategy's ~$40B Bitcoin holdings and Metaplanet's meteoric treasury transformation -  Following strategic divestiture, Prenetics leverages strengthened $117M balance sheet to execute comprehensive Bitcoin strategy with board-approved majority allocation, institutional financing partnerships, and alpha-generating initiatives. CHARLOTTE, N.C., June 18, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE), a leading health sciences company, today announced it has become the first healthcare company to establish a Bitcoin treasury, completing a $20 million Bitcoin purchase of 187.42 BTC at an averag

    6/18/25 8:45:00 AM ET
    $PRE
    Blank Checks
    Finance

    Prenetics Welcomes Kathyrn M. Henry and David Vanderveen to Board of Directors

    LOS ANGELES, July 01, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, welcomes Kathryn M. Henry and David Vanderveen as independent directors to the Company's Board of Directors. "We are excited to welcome Kathryn and David to Prenetics' Board of Directors at this pivotal juncture," said Danny Yeung, CEO of Prenetics. "Their unparalleled expertise in consumer and health sectors, combined with their proven leadership in driving global expansion and operational excellence, will significantly enhance shareholder value as we expand into consumer health and wellness." "I am thrilled to join Prenetics at such a p

    7/1/24 8:30:00 AM ET
    $PRE
    Blank Checks
    Finance

    Prenetics Announces MOU for a Strategic Investment and 5-Year Research Collaboration with Metavisionaries to Pioneer R&D on the International Space Station

    (From left: Dr. Ghada Alsaleh, Sonia Pawelczyk, Danny Yeung, Dr. James L. Green, Ahmed Alfandi, Dr. Tara Ruttley, Wasim Ahmed, Dr. Hilde Stenuit, Dr. Camille Alleyne at the MOU signing ceremony in Dubai, UAE Space Agency) Initial research project is with NDORMS, Botnar Research Institute, University of Oxford, focusing on accelerated aging in spaceDr. James L. Green, former Chief Scientist of NASA and Dr. Tara Ruttley, former Associate Chief Scientist of NASA to join Prenetics Scientific Advisory BoardInaugural research cube scheduled to be sent on-board SpaceX to the ISS in Q4 of 2024 DUBAI, United Arab Emirates, Feb. 09, 2024 (GLOBE NEWSWIRE) -- UAE Space Agency – Prenetics Global Li

    2/9/24 9:25:22 AM ET
    $PRE
    Blank Checks
    Finance

    $PRE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Prenetics Global Limited

    SC 13G/A - Prenetics Global Ltd (0001876431) (Subject)

    11/14/24 12:30:15 PM ET
    $PRE
    Blank Checks
    Finance

    SEC Form SC 13G/A filed by Prenetics Global Limited (Amendment)

    SC 13G/A - Prenetics Global Ltd (0001876431) (Subject)

    2/5/24 6:05:14 AM ET
    $PRE
    Blank Checks
    Finance

    SEC Form SC 13G/A filed by Prenetics Global Limited (Amendment)

    SC 13G/A - Prenetics Global Ltd (0001876431) (Subject)

    11/27/23 6:05:43 AM ET
    $PRE
    Blank Checks
    Finance